Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine

Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine
Panacea Pharmaceuticals has completed patient enrollment in a Phase 1 clinical trial testing its PAN-301-1 vaccine as a treatment for prostate cancer that has failed to respond to other therapies. The multi-center trial (NCT03120832) is looking at the vaccine's ability to provoke an immune response in prostate cancer patients who experienced a rise in their PSA levels after surgery or radiation therapy. PSA is a protein that doctors use as the main biomarker of prostate cancer. Panacea is conducting the trial, which began enrolling participants in January 2017, at four U.S. sites. PAN-301-1 targets human aspartyl (asparaginyl) β-hydroxylase, or HAAH, an enzyme usually not found in healthy cells, but present in more than 20 types of cancer. During fetal development, HAAH participates in cells' growth, movement, and interaction. But at birth, the body no longer produces it. In cancer cells, it is generally associated with a worse patient outlook. PAN-301-1 contains hundreds of copies of an HAAH fragment to generate an immune response against the enzyme. Panacea designed it to overcome the immune system’s ability to avoid attacking the body’s own proteins. The company has administered more than 90 doses to 12 patients. Each patient is receiving a minimum of three doses of PAN-301-1, using a fixed dose escalation protocol, every 21 days. The vaccine is administered under the skin, using the 
Subscribe or to access all post and page content.